Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.
about
Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgeryStatins for the primary prevention of cardiovascular diseaseNiacin for primary and secondary prevention of cardiovascular eventsFibrates for primary prevention of cardiovascular disease eventsLipid-lowering therapy: who can benefit?Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitusBenefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetesThe effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trialsMuscular effects of statins in the elderly female: a reviewPatient-Centered Interventions to Improve Adherence to Statins: A Narrative Synthesis of Systematically Identified StudiesPediatric Statin Administration: Navigating a Frontier with Limited DataSystematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipientsFibrates for primary prevention of cardiovascular disease events.Accuracy of low-density lipoprotein cholesterol estimation at very low levels.Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalinkUnintended effects of statins from observational studies in the general population: systematic review and meta-analysis.Niacin for primary and secondary prevention of cardiovascular events.Leukocytosis and enhanced susceptibility to endotoxemia but not atherosclerosis in adrenalectomized APOE knockout mice.Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristicsCost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins.Do Statins Reduce the Health and Health Care Costs of Obesity?Communicating statin evidence to support shared decision-making.Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort StudyA review of time courses and predictors of lipid changes with fenofibric acid-statin combination.Statins can delay insulin use and reduce diabetes-related diseases in Asian patients with type 2 diabetesEffects of Long-Term Statin Therapy in Coronary Artery Disease Patients with or without Chronic Kidney Disease.Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study.Time trends in statin utilisation and coronary mortality in Western European countries.Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival.Association of statin use and stress-induced hyperglycemia in patients with acute ST-elevation myocardial infarction.Cholesterol and cardiovascular disease in the elderly. Facts and gaps.Risk of incident diabetes among patients treated with statins: population based study.Acute kidney injury in statin initiators.The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study.Statins and risk for new-onset diabetes mellitus: A real-world cohort study using a clinical research database.Diabetogenic effect of statins: a double-edged sword?Marital status shows a strong protective effect on long-term mortality among first acute myocardial infarction-survivors with diagnosed hyperlipidemia--findings from the MONICA/KORA myocardial infarction registry.Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study.
P2860
Q24201360-72E06F1D-A165-423A-9573-50E856939616Q24201513-8425E34C-4DFE-4EB9-B181-1DCBED59060AQ24203613-03537048-BA12-450B-BF57-495931AFB9ACQ24203618-B1393098-2C88-4081-98BA-07BA9F5D1F2AQ26827432-53F8BC82-38F3-4CE0-886F-5E2C5E063C5EQ26829529-16DDCAC3-CB50-4A25-90A0-15C25AED770AQ26853571-62224C6E-0F8A-4AE6-A3D1-33D41F94AD76Q26999003-DE399BE8-9DEF-43DD-826C-1FE3EF474BFDQ27023343-0301AFB0-21FB-4AA9-835D-020DE319E0C3Q28066001-E3361D9B-9AD2-4D8C-B1BD-65418CA276A6Q28068014-559CF412-43E5-4778-9BEA-5A9D743CE497Q28083874-135FFE46-D960-4043-8B87-B919E0C1675DQ30241199-A5A9F5FE-D577-4F80-8EEF-79910C989855Q33587438-DC8851E1-B887-4B2A-B21A-CAA0CC15F63AQ33776187-F3F4708F-FA46-475C-A0F9-8C256597DB43Q33986300-D930FC6C-91E0-46BA-B492-75A1D66A575FQ34411415-81B61296-B25C-45F8-843E-0DABE7023C37Q34682221-87D8BABE-A28F-4BAE-9495-2695BF8C1411Q35050657-CACFA3BC-DFC8-4656-A667-92E7D376579AQ35100483-A67785F4-9B35-4C38-8541-7145DE8DB90FQ35292482-A8612F05-E2FB-4A15-BD29-41FA1A70146BQ35734332-96B1FB76-FB23-4B4E-AE09-56D75D2DA7F2Q35812297-ED10F55E-3A68-4801-9683-8FE567A5A825Q35980419-A20F85DE-23DB-437D-8F0D-58EFB79F0EE0Q36009362-FD024E54-9428-41CB-8D25-3751AB4B2FB3Q36011053-200FA6AF-A370-4E6C-9FD5-F4B8105AD8B5Q36153656-AA8E3699-1F67-4C1B-BAF7-FA4BFCF88C25Q36199235-692C3D92-EADD-44D4-90B9-8D76193AE79BQ36311785-E25B76C9-87E5-4A5A-BAEA-4CBA1DABCC09Q36773079-822D9AAF-54AA-49E7-B6C4-DF58F1158C23Q36782651-3262731C-DF8B-4D22-9557-629AD16E74A0Q36835349-006995EC-AC3D-4190-9CAA-0B2EB5356884Q36863052-75D4AF23-7AE6-4EC4-8DE3-08AB1366B5C8Q36871618-E0C3D5FC-3691-45BC-A4A2-EC5CD6A7B929Q37293690-A9DF89FE-78F2-451A-AB55-9415CA9B75ECQ37342403-5834471D-90EB-4510-A262-BDE5440CA2A4Q37433115-47CD6992-AEEE-472C-912B-289A0A998046Q37435688-9CDBEE92-BC08-4E88-8D46-C9E38F727F73Q37607668-E2E34E85-6B91-4B70-BC13-69B9BFBF156CQ37612171-D2CD5746-1A86-43F2-9599-A2C56E571463
P2860
Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efficacy and safety of statin ...... nts from 76 randomized trials.
@ast
Efficacy and safety of statin ...... nts from 76 randomized trials.
@en
Efficacy and safety of statin ...... nts from 76 randomized trials.
@nl
type
label
Efficacy and safety of statin ...... nts from 76 randomized trials.
@ast
Efficacy and safety of statin ...... nts from 76 randomized trials.
@en
Efficacy and safety of statin ...... nts from 76 randomized trials.
@nl
prefLabel
Efficacy and safety of statin ...... nts from 76 randomized trials.
@ast
Efficacy and safety of statin ...... nts from 76 randomized trials.
@en
Efficacy and safety of statin ...... nts from 76 randomized trials.
@nl
P2093
P2860
P50
P921
P356
P1476
Efficacy and safety of statin ...... nts from 76 randomized trials.
@en
P2093
O Berwanger
P2860
P304
P356
10.1093/QJMED/HCQ165
P407
P577
2010-10-07T00:00:00Z